RTTNews | May 4, 2021 10:08AM EDT

10:08 Tuesday, May 4, 2021 (RTTNews.com) - BioLineRx Ltd. (BLRX) shares are gaining more than 83 percent on Tuesday morning trade, on more than average volume, after the company said its Genesis phase 3 trial of Motixafortide in multiple myeloma patients met all primary and secondary endpoints.

Currently, shares are at $5.67, up 77.74 percent from the previous close of $3.19 on a volume of 74,739,779. The shares have traded in a range of $1.40-$6.09 on average volume of 971,167.

The late clinical-stage biopharmaceutical company noted that all 122 enrolled patients well tolerated the drug candidate and found highly statistically significant evidence favoring Motixafortide in addition to G-CSF.

Read the original article on RTTNews ( https://www.rttnews.com/3191369/stock-alert-biolinerx-spikes-83-on-positive-phase-3-trial-of-motixafortide-in-multiple-myeloma.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved